The CRYOSTAT2 trial: The rationale and study protocol for a multi‐Centre, randomised, controlled trial evaluating the effects of early high‐dose cryoprecipitate in adult patients with major trauma haemorrhage requiring major haemorrhage protocol activation
Authors:
- 2 November 2022
- journal article
- research article
- Published by Wiley in Transfusion Medicine
- Vol. 33 (2) , 123-131
Abstract
Objectives: To describe the protocol for a multinational randomised, parallel, superiority trial, in which patients were randomised to receive early high‐dose cryoprecipitate in addition to standard major haemorrhage protocol (MHP), or Standard MHP alone.Background: Blood transfusion support for trauma‐related major bleeding includes red cells, plasma and platelets. The role of concentrated sources of fibrinogen is less clear and has not been evaluated in large clinical trials. Fibrinogen is a key pro‐coagulant factor that is essential for stable clot formation. A pilot trial had demonstrated that it was feasible to deliver cryoprecipitate as a source of fibrinogen within 90 min of admission.Methods: Randomisation was via opaque sealed envelopes held securely in participating Emergency Departments or transfusion laboratories. Early cryoprecipitate, provided as 3 pools (equivalent to 15 single units of cryoprecipitate or 6 g fibrinogen supplementation), was transfused as rapidly as possible, and started within 90 min of admission. Participants in both arms received standard treatment defined in the receiving hospital MHP. The primary outcome measure was all‐cause mortality at 28 days. Symptomatic thrombotic events including venous thromboembolism and arterial thrombotic events (myocardial infarction, stroke) were collected from randomisation up to day 28 or discharge from hospital. EQ5D‐5Land Glasgow Outcome Score were completed at discharge and 6 months. All analyses will be performed on an intention to treat basis, with per protocol sensitivity analysis.Results: The trial opened for recruitment in June 2017 and the final patient completed follow‐up in May 2022.Discussion: This trial will provide firmer evidence to evaluate the effectiveness and cost‐effectiveness of early high‐dose cryoprecipitate alongside the standard MHP in major traumatic haemorrhage.Keywords
Funding Information
- National Institute for Health Research
This publication has 32 references indexed in Scilit:
- Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomesJournal of Thrombosis and Haemostasis, 2012
- The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trialThe Lancet, 2011
- Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trialThe Lancet, 2010
- Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM®)-guided administration of fibrinogen concentrate and prothrombin complex concentrateCritical Care, 2010
- Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patientsTransfusion, 2010
- Improvements in Early Mortality and Coagulopathy are Sustained Better in Patients With Blunt Trauma After Institution of a Massive Transfusion Protocol in a Civilian Level I Trauma CenterJournal of Trauma: Injury, Infection & Critical Care, 2009
- Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trialJournal of Thrombosis and Haemostasis, 2009
- The Ratio of Fibrinogen to Red Cells Transfused Affects Survival in Casualties Receiving Massive Transfusions at an Army Combat Support HospitalJournal of Trauma: Injury, Infection & Critical Care, 2008
- Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high‐risk severe bleedingVox Sanguinis, 2008
- Hemostatic Factors and Replacement of Major Blood Loss with Plasma-Poor Red Cell ConcentratesAnesthesia & Analgesia, 1995